SantoSolveAS, an Oslo, Norway-based drug developer focused on pain therapeutics, has raised $7 million in new VC funding. Its lead candidate is for osteoarthritis. DnBNor, Gezina and Glastad Invest were joined on the round by return backers Teknoinvest and InnovationsKapital. www.santosolve.com
Nearly there!
We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case
it’s been delivered there.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.
Copyright PEI Media
Not for publication, email or dissemination
Share with other subscribers
Only logged in subscribers of this site will be able to access the shared article.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.